- 1.
Rajkumar SV, Dimopoulos MA, Palumbo A et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538–48. [PubMed][CrossRef]
- 2.
Wisløff F, Andersen P, Andersson TR et al. Has the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region I in Norway. I. Eur J Haematol 1991; 47: 333–7. [PubMed][CrossRef]
- 3.
Kyle RA, Therneau TM, Rajkumar SV et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362–9. [PubMed][CrossRef]
- 4.
Landgren O, Kyle RA, Pfeiffer RM et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412–7. [PubMed][CrossRef]
- 5.
Kreftregisterets årsrapport for lymfoide maligniteter. Oslo: Kreftregisteret, 2018. https://www.kreftregisteret.no/Generelt/Rapporter/Arsrapport-fra-kvalitetsregistrene/Arsrapport-for-lymfom-og-KLL/ Lest 1.3.2021.
- 6.
Rajkumar SV, Kyle RA, Therneau TM et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812–7. [PubMed][CrossRef]
- 7.
Go RS, Gundrum JD, Neuner JM. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Clin Lymphoma Myeloma Leuk 2015; 15: 177–186.e4. [PubMed][CrossRef]
- 8.
Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108: 2520–30. [PubMed][CrossRef]
- 9.
Bida JP, Kyle RA, Therneau TM et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc 2009; 84: 685–93. [PubMed][CrossRef]
- 10.
Sipe JD, Benson MD, Buxbaum JN et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014; 21: 221–4. [PubMed][CrossRef]
- 11.
Kyle RA, Linos A, Beard CM et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79: 1817–22. [PubMed][CrossRef]
- 12.
Hemminki K, Li X, Försti A et al. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health 2012; 12: 974. [PubMed][CrossRef]
- 13.
Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am 1999; 13: 1235–48. [PubMed][CrossRef]
- 14.
Berentsen S, Ulvestad E, Langholm R et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 2006; 91: 460–6. [PubMed]
- 15.
Randen U, Trøen G, Tierens A et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica 2014; 99: 497–504. [PubMed][CrossRef]
- 16.
Berentsen S, Malecka A, Randen U et al. Cold agglutinin disease: where do we stand, and where are we going? Clin Adv Hematol Oncol 2020; 18: 35–44. [PubMed]
- 17.
Ferri C, Sebastiani M, Giuggioli D et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33: 355–74. [PubMed][CrossRef]
- 18.
Dalakas MC. Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. Ther Adv Neurol Disord 2018; 11: 1756285617746640. [PubMed][CrossRef]
- 19.
Fermand JP, Bridoux F, Dispenzieri A et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood 2018; 132: 1478–85. [PubMed][CrossRef]
- 20.
Li J, Huang Z, Duan MH et al. Characterization of immunoglobulin λ light chain variable region (IGLV) gene and its relationship with clinical features in patients with POEMS syndrome. Ann Hematol 2012; 91: 1251–5. [PubMed][CrossRef]
- 21.
Berentsen S, Barcellini W, D'Sa S et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood 2020; 136: 480–8. [PubMed][CrossRef]
- 22.
Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: A systematic review. JAMA 2020; 324: 79–89. [PubMed][CrossRef]
- 23.
Norsk selskap for hematologi. Handlingsprogram. https://www.legeforeningen.no/foreningsledd/fagmed/Norsk-selskap-for-hematologi/handlingsprogram/ Lest 1.3.2021.
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.